Reassessing the cryopreserved human amniotic membrane's low immunogenicity due to advances in histocompatibility
Abstract
Human amniotic membrane (hAM) is a biocompatible scaffold with suitable mechanical properties (permeability, stability, elasticity, flexibility, resorbability and transparency), that is rich in stem cells and growth factors and is used for tissue repair and regenerative processes. It is routinely used in ocular surgery as it promotes epithelialization, supports cell adhesion and proliferation, and enhances wound healing. It exhibits both immunomodulatory and immunoregulatory properties, contributing to its anti-inflammatory and low immunogenicity risk profile. hAM transplantation is considered unlikely to trigger an immune response against human leukocyte antigens (HLA) and is generally regarded as minimally or non-immunogenic. This conclusion is primarily based on clinical observations, and a single study published 40 years ago that investigated subcutaneous hAM grafting-a procedure that does not reflect current clinical applications. Since then, there has been no laboratory evidence that hAM transplantation is immunologically safe. Notably, the production of anti-HLA antibodies following hAM transplantation has not been investigated, despite the tremendous improvements in the sensitivity of detection techniques. The recent application of hAM to more vascularized areas could raise concerns about potential immune responses. In this perspective paper, we summarize the limited and sometimes contradictory data regarding hAM immunogenicity. Then, we describe the methods we use to assess whether immune responses are triggered after hAM grafting in current clinical indications.
Related
- Minimal immune response after transplantation of a cryopreserved human amniotic membrane on the ocular surface
- Vision-Related Quality of Life and Dry Eye Symptoms After Treatment with Lyophilized Amniotic Membrane Eye Drops: A Secondary Analysis of a Prospective Cohort Study
- Late-onset spontaneous chorioamniotic membrane separation mimicking amniotic band sequence with rapid progression to preterm premature rupture of membranes
- Glass intraocular foreign body removal assisted by biological amniotic membrane: a case report
- Effects of glycerol processing on the biomechanical, structural, optical, and antimicrobial properties of human amniotic membrane.
BibTeX
@article{baudey2026reassessing,
title = {{Reassessing the cryopreserved human amniotic membrane's low immunogenicity due to advances in histocompatibility}},
author = {Jean-Baptiste Baudey and Lauriana Solecki and Christophe Picard and Pascal Pedini and Bastien Mathéaud and Alain Coaquette and Isabelle Jollet and Pauline Jamain and Lucas Hubert and Adeline Desanlis and Xavier Lafarge and Florelle Gindraux},
journal = {Materials Today Bio},
year = {2026},
month = sep,
doi = {10.1016/j.mtbio.2025.102619},
url = {https://hal.science/hal-05756929v1},
note = {CC BY},
}
RIS
TY - JOUR
TI - Reassessing the cryopreserved human amniotic membrane's low immunogenicity due to advances in histocompatibility
AU - Jean-Baptiste Baudey
AU - Lauriana Solecki
AU - Christophe Picard
AU - Pascal Pedini
AU - Bastien Mathéaud
AU - Alain Coaquette
AU - Isabelle Jollet
AU - Pauline Jamain
AU - Lucas Hubert
AU - Adeline Desanlis
AU - Xavier Lafarge
AU - Florelle Gindraux
PY - 2026
DA - 2026/09/21
JO - Materials Today Bio
DO - 10.1016/j.mtbio.2025.102619
UR - https://hal.science/hal-05756929v1
AB - Human amniotic membrane (hAM) is a biocompatible scaffold with suitable mechanical properties (permeability, stability, elasticity, flexibility, resorbability and transparency), that is rich in stem cells and growth factors and is used for tissue repair and regenerative processes. It is routinely used in ocular surgery as it promotes epithelialization, supports cell adhesion and proliferation, and enhances wound healing. It exhibits both immunomodulatory and immunoregulatory properties, contributing to its anti-inflammatory and low immunogenicity risk profile. hAM transplantation is considered unlikely to trigger an immune response against human leukocyte antigens (HLA) and is generally regarded as minimally or non-immunogenic. This conclusion is primarily based on clinical observations, and a single study published 40 years ago that investigated subcutaneous hAM grafting-a procedure that does not reflect current clinical applications. Since then, there has been no laboratory evidence that hAM transplantation is immunologically safe. Notably, the production of anti-HLA antibodies following hAM transplantation has not been investigated, despite the tremendous improvements in the sensitivity of detection techniques. The recent application of hAM to more vascularized areas could raise concerns about potential immune responses. In this perspective paper, we summarize the limited and sometimes contradictory data regarding hAM immunogenicity. Then, we describe the methods we use to assess whether immune responses are triggered after hAM grafting in current clinical indications.
SN - 2590-0064
ER -